Literature DB >> 31481465

Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation.

Hiroshi Deguchi1, Zihan Guo1, Mohammed Hayat1, Elsa Pflimlin2, Sam Lear2, Weijun Shen3, John H Griffin4.   

Abstract

Skeletal muscle myosin has potent procoagulant activity that is based on its ability to enhance thrombin generation due to binding coagulation factors Xa and Va and accelerating prothrombin activation. A well-studied myosin inhibitor that binds to myosin's neck region inhibits myosin-dependent prothrombin activation. Hence, to identify a potential binding site(s) on skeletal muscle myosin for factor Xa, 19 peptides (25-40 residues) representing the neck region, which consists of a regulatory light chain, an essential light chain, and a heavy chain (HC), were screened for inhibition of myosin-supported prothrombin activation. Peptide HC796-835 comprising residues 796-835 of the heavy chain strongly inhibited myosin-enhanced prothrombin activation by factors Xa and Va (50% inhibition at 1.2 μm), but it did not inhibit phospholipid vesicle-enhanced prothrombin activation. Peptide inhibition studies also implicated several myosin light chain sequences located near HC796-835 as potential procoagulant sites. A peptide comprising HC796-835's C-terminal half, but not a peptide comprising its N-terminal half, inhibited myosin-enhanced prothrombin activation (50% inhibition at 1.2 μm). This inhibitory peptide (HC816-837) did not inhibit phospholipid-enhanced prothrombin activation, indicating its specificity for inhibition of myosin-dependent procoagulant mechanisms. Binding studies showed that purified factor Xa was bound to immobilized peptides HC796-835 and HC816-837 with apparent Kd values of 0.78 and 1.3 μm, respectively. In summary, these studies imply that HC residues 816-835 in the neck region of the skeletal muscle myosin directly bind factor Xa and, with contributions from light chain residues in this neck region, contribute to provision of myosin's procoagulant surface.
© 2019 Deguchi et al.

Entities:  

Keywords:  coagulation factor; factor Xa; myosin; peptides; skeletal muscle; thrombin

Mesh:

Substances:

Year:  2019        PMID: 31481465      PMCID: PMC6791324          DOI: 10.1074/jbc.AC119.010236

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Phosphorylated smooth muscle heavy meromyosin shows an open conformation linked to activation.

Authors:  Bruce A J Baumann; Dianne W Taylor; Zhong Huang; Florence Tama; Patricia M Fagnant; Kathleen M Trybus; Kenneth A Taylor
Journal:  J Mol Biol       Date:  2011-11-04       Impact factor: 5.469

2.  Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids.

Authors:  Hiroshi Deguchi; Darlene J Elias; Sunia Trauger; Hui-Min Zhang; Ewa Kalisiak; Gary Siuzdak; John H Griffin
Journal:  Br J Haematol       Date:  2014-01-23       Impact factor: 6.998

3.  EPR and CD spectroscopy of fast myosin light chain conformation during binding of trifluoperazine.

Authors:  W Huang; G J Wilson; L J Brown; H Lam; B D Hambly
Journal:  Eur J Biochem       Date:  1998-10-15

4.  On the mode of the alkali light chain association to the heavy chain of myosin subfragment 1. Evidence for the involvement of the carboxyl-terminal region of the heavy chain.

Authors:  M Burke; M Sivaramakrishnam; V Kamalakannan
Journal:  Biochemistry       Date:  1983-06-21       Impact factor: 3.162

5.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

6.  Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis.

Authors:  P Erlacher; A Lercher; J Falkensammer; E L Nassonov; M I Samsonov; V Z Shtutman; B Puschendorf; J Mair
Journal:  Clin Chim Acta       Date:  2001-04       Impact factor: 3.786

7.  Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.

Authors:  Claes Held; Elaine M Hylek; John H Alexander; Michael Hanna; Renato D Lopes; Daniel M Wojdyla; Laine Thomas; Hussein Al-Khalidi; Marco Alings; Dennis Xavier; Jack Ansell; Shinya Goto; Witold Ruzyllo; Mårten Rosenqvist; Freek W A Verheugt; Jun Zhu; Christopher B Granger; Lars Wallentin
Journal:  Eur Heart J       Date:  2014-12-12       Impact factor: 29.983

8.  Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.

Authors:  Hiroshi Deguchi; Ranjeet K Sinha; Patrizia Marchese; Zaverio M Ruggeri; Jevgenia Zilberman-Rudenko; Owen J T McCarty; Mitchell J Cohen; John H Griffin
Journal:  Blood       Date:  2016-07-15       Impact factor: 22.113

9.  Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis. Diagnostic specificity of new biochemical markers.

Authors:  M Löfberg; R Tähtelä; M Härkönen; H Somer
Journal:  Arch Neurol       Date:  1995-12

10.  Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.

Authors:  Xiaoyan Shawn Li; Steve Deitelzweig; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2017-03-16       Impact factor: 5.249

View more
  8 in total

1.  Procoagulant activities of skeletal and cardiac muscle myosin depend on contaminating phospholipid.

Authors:  Valerie A Novakovic; Gary E Gilbert
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

2.  Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Hiroshi Deguchi; Meenal Shukla; Yoshimasa Oyama; Jennifer N Orje; Zihan Guo; Tine Wyseure; Laurent O Mosnier; Owen J T McCarty; Zaverio M Ruggeri; Tobias Eckle; John H Griffin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

3.  Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults.

Authors:  Taichi K Deguchi; Hiroshi Deguchi; Zihan Guo; Darlene J Elias; John H Griffin
Journal:  Thromb Res       Date:  2020-02-27       Impact factor: 3.944

Review 4.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

5.  Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids.

Authors:  Shravan Morla; Hiroshi Deguchi; José A Fernández; Wolfram Ruf; Rolf A Brekken; John H Griffin
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

6.  Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation.

Authors:  Shravan Morla; Hiroshi Deguchi; Jevgenia Zilberman-Rudenko; András Gruber; Owen J T McCarty; Priyanka Srivastava; David Gailani; John H Griffin
Journal:  J Biol Chem       Date:  2022-01-07       Impact factor: 5.157

7.  Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients.

Authors:  Julia R Coleman; Hiroshi Deguchi; Taichi K Deguchi; Mitchel J Cohen; Ernest E Moore; John H Griffin
Journal:  J Thromb Haemost       Date:  2022-03-20       Impact factor: 16.036

8.  Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.

Authors:  Shravan Morla; Hiroshi Deguchi; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-12-10       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.